Skip to main navigation Skip to search Skip to main content

S737 Effect of Risankizumab on Patient-Reported Outcomes in Patients With Crohns Disease With Inadequate Response or Intolerance to Conventional And/or Biologic Treatments: Results From Phase 3 MOTIVATE and ADVANCE Trials

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalAmerican Journal of Gastroenterology
DOIs
Publication statusPublished - 2021

Keywords

  • Medicine
  • Placebo
  • Internal medicine
  • Crohns disease
  • Inflammatory bowel disease
  • Adverse effect
  • Gastroenterology
  • Randomized controlled trial
  • Physical therapy
  • Disease
  • Alternative medicine
  • Pathology

Cite this